https://insightsemerge.com/press-releases/immunitybio-reports-label-expansion-and-additional-global-approval-with-q3-2026-netInsights Emergeen2026-11-09T13:02:59.175ZImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million https://insightsemerge.com/press-releases/compugen-reports-third-quarter-2026-resultsInsights Emergeen2026-11-09T12:23:11.021ZCompugen Reports Third Quarter 2026 Results https://insightsemerge.com/roundups/business-week-of-nov-2-2026Insights Emergeen2026-11-09T14:57:00.000ZDeals and debt shape third-quarter results: the week in business https://insightsemerge.com/roundups/biotech-and-pharma-week-of-nov-2-2026Insights Emergeen2026-11-09T14:46:00.000ZQ3 results put cash runways and 2027 FDA timelines in focus https://insightsemerge.com/roundups/health-and-medical-week-of-nov-2-2026Insights Emergeen2026-11-09T14:35:00.000ZQ3 results bring raised guidance, CVS plans split: health week